Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications
Background The COVID-19 pandemic caused by SARS-CoV-2 coronavirus threatens global
public health. Currently, neutralizing antibodies (NAbs) versus this virus are expected to …
public health. Currently, neutralizing antibodies (NAbs) versus this virus are expected to …
[HTML][HTML] rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with …
TP Monath, PE Fast, K Modjarrad, DK Clarke… - Vaccine: X, 2019 - Elsevier
Abstract The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG)
was formed to evaluate the safety and characteristics of live, recombinant viral vector …
was formed to evaluate the safety and characteristics of live, recombinant viral vector …
Neglected filoviruses
R Burk, L Bollinger, JC Johnson, J Wada… - FEMS microbiology …, 2016 - academic.oup.com
Eight viruses are currently assigned to the family Filoviridae. Marburg virus, Sudan virus
and, in particular, Ebola virus have received the most attention both by researchers and the …
and, in particular, Ebola virus have received the most attention both by researchers and the …
[HTML][HTML] Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection
Antibodies are promising post-exposure therapies against emerging viruses, but which
antibody features and in vitro assays best forecast protection are unclear. Our international …
antibody features and in vitro assays best forecast protection are unclear. Our international …
[HTML][HTML] Analysis of a therapeutic antibody cocktail reveals determinants for cooperative and broad ebolavirus neutralization
Structural principles underlying the composition of protective antiviral monoclonal antibody
(mAb) cocktails are poorly defined. Here, we exploited antibody cooperativity to develop a …
(mAb) cocktails are poorly defined. Here, we exploited antibody cooperativity to develop a …
[HTML][HTML] Combination therapy protects macaques against advanced Marburg virus disease
Monoclonal antibodies (mAbs) and remdesivir, a small-molecule antiviral, are promising
monotherapies for many viruses, including members of the genera Marburgvirus and …
monotherapies for many viruses, including members of the genera Marburgvirus and …
[HTML][HTML] Antibody-dependent enhancement of Ebola virus infection by human antibodies isolated from survivors
Some monoclonal antibodies (mAbs) recovered from survivors of filovirus infections can
protect against infection. It is currently unknown whether natural infection also induces some …
protect against infection. It is currently unknown whether natural infection also induces some …
[HTML][HTML] Pan-ebolavirus protective therapy by two multifunctional human antibodies
Ebolaviruses cause a severe and often fatal illness with the potential for global spread.
Monoclonal antibody-based treatments that have become available recently have a narrow …
Monoclonal antibody-based treatments that have become available recently have a narrow …
[HTML][HTML] Non-neutralizing antibodies from a Marburg infection survivor mediate protection by Fc-effector functions and by enhancing efficacy of other antibodies
Marburg virus (MARV) and Ebola virus (EBOV) belong to the family Filoviridae. MARV
causes severe disease in humans with high fatality. We previously isolated a large panel of …
causes severe disease in humans with high fatality. We previously isolated a large panel of …
Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2–MPER region
Ebola virus (EBOV) in humans causes a severe illness with high mortality rates. Several
strategies have been developed in the past to treat EBOV infection, including the antibody …
strategies have been developed in the past to treat EBOV infection, including the antibody …